Compositions Comprising Pharmaceutically Acceptable Salts of Glucagon-Like PEPTIDE-1 Analogs and Uses Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/US2022/049585, filed Nov 10, 2022. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,233,110 | Compositions Comprising Pharmaceutically Acceptable Salts of Glucagon-Like PEPTIDE-1 Analogs and Uses Thereof In force · Medium confidence UsedRemaining | I2O Therapeutics, Inc. | In force | Medium confidence | ||
| US 12,233,111 | Compositions Comprising Pharmaceutically Acceptable Salts of Glucagon-Like PEPTIDE-1 Analogs and Uses Thereof In force · Medium confidence | I2O Therapeutics, Inc. | In force | Medium confidence | ||
| US 12,233,112 | Compositions Comprising Pharmaceutically Acceptable Salts of Amylin Analogs and Uses Thereof In force · Medium confidence | I2O Therapeutics, Inc. | In force | Medium confidence | ||
| US 12,337,029 | Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof In force · Low confidence | I2O Therapeutics, Inc. | In force | Low confidence | ||
| US 12,350,320 | Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and pharmaceutically acceptable salts of amylin analogs, and uses thereof In force · Medium confidence | I2O Therapeutics, Inc. | In force | Medium confidence | ||
| Application 18/946,213 | Compositions Comprising Therapeutic Proteins or Peptides, and Uses Thereof Pending Not granted | I2O Therapeutics, Inc. | Pending | Not granted | ||
| Application 18/960,864 | Method of Treating Disease or Disorder Using Compositions Comprising Pharmaceutically Acceptable Salts of Amylin Analogs Pending Not granted | I2O Therapeutics, Inc. | Pending | Not granted |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by I2O Therapeutics, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.